Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > ARVN Arvinas > Detailed Quotes

ARVN Arvinas

44.220
+0.980+2.27%
Trading Session 09/28 09:55 ET
High
44.740
Open
44.330
Turnover
1.76M
Low
43.590
Pre Close
43.240
Volume
39.90K
Market Cap
2.35B
P/E(TTM)
Loss
52wk High
97.330
Shares
53.21M
P/E(Static)
Loss
52wk Low
34.900
Float Cap
1.80B
Bid/Ask %
0.00%
Historical High
108.465
Shs Float
40.70M
Volume Ratio
1.81
Historical Low
10.190
Dividend TTM
--
Div Yield TTM
--
P/B
3.51
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.10%
Amplitude
2.66%
Avg Price
44.173
Lot Size
1
Float Cap
1.80B
Bid/Ask %
0.00%
Historical High
108.465
Shs Float
40.70M
Volume Ratio
1.81
Historical Low
10.190
Dividend TTM
--
P/B
3.51
Dividend LFY
--
Turnover Ratio
0.10%
Amplitude
2.66%
Avg Price
44.173
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.
CEO: Dr. John G. Houston, PhD
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...